ASPI news

Renergen's Virginia Gas Project completed commissioning, producing stable liquid helium for the first time. This milestone impacts ASP Isotopes by providing a critical supply chain addition for helium, an essential industrial material.

Quantum Leap Energy, a subsidiary of ASP Isotopes, signed a binding joint venture agreement with Necsa to produce commercial-scale High-Assay Low-Enriched Uranium (HALEU) in South Africa, supported by offtake agreements with TerraPower and initial regulatory approvals.

ASP Isotopes held its inaugural Capital Markets Day outlining strategies across nuclear medicine and other sectors while targeting over $300M of cumulative EBITDA by 2031. The company announced plans for public listings of Quantum Leap Energy and Noble Africa.

Subsidiary inc. agreed to amend a facility agreement with Standard Bank of South Africa, subject to conditions precedent.

ASP Isotopes subsidiary Quantum Leap Energy is initiating a pilot-scale metal conversion facility in Namibia to evaluate nuclear fuel cycle processes, driven by the global demand for advanced nuclear reactor components and fusion systems.

ASP Isotopes announced it will host investor meetings at Citi's 2026 Natural Resources Conference in Las Vegas on August 13, 2026. The announcement also covers a proposed merger with Endra Life Sciences.

ASP Isotopes initiatives targeting critical materials are progressing, with revenue expectations for 1H 2026 increasing by more than 50% and the company achieving key inflection points. The news reinforces the company's bullish outlook regarding profitability and long-term EBITDA targets.

ASP Isotopes announced CCO Viktor Petkov will speak at the Canaccord Genuity Growth Conference on August 12, 2026. This provides investors with an update on the company's differentiated isotope enrichment platforms and upcoming Proposed Transactions.

ASP Isotopes announced its first-ever Capital Markets Day in London on September 8 to provide an overview of its strategy in critical materials. The event will focus on nuclear medicine, electronic gases, and nuclear fuels, and is intended to bolster investor interest in its proprietary isotope enri…

ASP Isotopes' subsidiary Quantum Leap Energy signed a research agreement with Texas A&M, aiming to de-risk and scale the commercial production of uranium hexafluoride for the U.S. nuclear fuel supply chain.

EisnerAmper LLP granted consent to incorporate its audit report into ASP Isotopes' S-3 and S-8 registration statements. This administrative filing supports the company's ongoing capital-raising objectives.

ASP Isotopes Inc. and partners entered into a definitive agreement on a merger plan. The transaction is set to close in June 2026.

ASP Isotopes subsidiary Noble Africa proposed merging with ENDRA Life Sciences subsidiary to form a Nasdaq-listed helium platform under ticker NOBA, backed by $50 million in financing. The deal establishes a public market vehicle for Renergen's helium project amid supply constraints.

Renergen, an ASP subsidiary, signed a five-year take-or-pay contract with an Asian buyer for helium at prices above $600/MCF, ensuring cash flow for Phase 1 operations. The agreement de-risks the 2026 commercial timeline and strengthens ASP's position in the critical materials market amidst global s…

ASP Isotopes successfully restarted the first 18 stages of its Silicon-28 enrichment facility after nine months of engineering modifications to non-core components. The company expects to commence commercial shipments of enriched Silicon-28 in Q3 2026 to three U.S. customers, with the material criti…